BOJ Minutes Signal More Rate Hikes as Inflation Risks Grow 
Philippine GDP Growth Slows to 2.3% in Q2 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
Singapore Says One-Third of U.S. Exports Hit by New 12.5% Tariff 
UK Services PMI Returns to Growth in July as New Orders and Confidence Rebound 
Gold Prices Steady as Hormuz Tensions Fuel Fed Rate Concerns 
Oil Prices Surge as Iran Hormuz Restrictions Renew Supply Fears 
Wall Street Ends Mixed as Dow Hits Record Despite Tech Weakness 
BOJ Rate Hike Expectations Rise Ahead of September Meeting 
Asian Currencies Hold Steady as US Dollar Nears Seven-Week Low Ahead of Key Jobs Data 
China Trade Surplus Beats Forecasts in July as Exports Stay Strong 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
German Bund Yields Hit Three-Week Low as Energy Prices Ease and ECB Outlook Softens 
European Stocks Near Record Highs as Earnings Strength Offsets Geopolitical Concerns 
Australia Trade Surplus Returns in June as Iron Ore, Coal and LNG Exports Surge 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
Oil Prices Slip as Hormuz Shipping Progress and Rising U.S. Crude Stocks Weigh on Market 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
